Introduction
============

Numerous diseases, including cancer require modulation in the immune system for disease management and care ([@b1-mmr-17-02-3035]). Under the circumstance of weakened immune responsiveness, the host protection machinery has to be activated to provide an alternative to conventional chemotherapy ([@b2-mmr-17-02-3035]). Potential immunomodulatory agents ([@b3-mmr-17-02-3035],[@b4-mmr-17-02-3035]) have been identified based on the observed therapeutic effects of phytochemicals isolated from various plants ([@b5-mmr-17-02-3035]--[@b7-mmr-17-02-3035]), and segregates of microorganisms and mammalian proteins, including immune mediators and certain synthetic chemicals ([@b8-mmr-17-02-3035]).

The triterpene alcohol, betulin and its equivalent carboxylic acid, betulinic acid (BetA; [Fig. 1](#f1-mmr-17-02-3035){ref-type="fig"}) are isolated from betula birch bark ([@b9-mmr-17-02-3035]), which has been used for various medicinal purposes in many countries ([@b10-mmr-17-02-3035]). BetA is a pentacyclic lupane-type triterpenoid of which a wide range of biological properties have been shown against cancer, inflammation, malaria, and helmintic and viral activities ([@b11-mmr-17-02-3035]--[@b14-mmr-17-02-3035]). Among these, the anticancer and cytotoxic activities of BetA have received significant attention ([@b15-mmr-17-02-3035],[@b16-mmr-17-02-3035]). Selective cytotoxicity has been demonstrated in multiple tumor cell lines ([@b15-mmr-17-02-3035]--[@b19-mmr-17-02-3035]) without effect in normal cells, including dermal fibroblasts and peripheral blood lymphocytes ([@b20-mmr-17-02-3035]--[@b22-mmr-17-02-3035]). Furthermore, no systemic toxic effects have been observed in rodents ([@b23-mmr-17-02-3035]). However, BetA is considered to be a weak antineoplastic agent, as it is required at micromolar concentrations to inhibit cell proliferation *in vitro*, and even higher doses are required (250 mg/kg body weight) to control melanoma growth in athymic mice ([@b24-mmr-17-02-3035]).

Despite a lack of toxicity, the poor potency of BetA hinders its clinical development. Mullauer *et al* ([@b23-mmr-17-02-3035]) cautioned that existing *in vivo* data are insufficient to support that BetA does not cause an effect on healthy cells. Furthermore, in contrast to previous findings, a recent study by Heiss *et al* ([@b24-mmr-17-02-3035]) reported that 10 µM BetA induces changes in normal cellular metabolism. The study by Heiss *et al* ([@b24-mmr-17-02-3035]) raised concerns regarding the clinical application of BetA and prompted us to investigate whether BetA may cause any major effects on healthy cells in the immune organs of mice.

Nitric oxide (NO) is a free radical and ubiquitous signaling molecule ([@b25-mmr-17-02-3035],[@b26-mmr-17-02-3035]) present in immune and endocrine tissues, among others ([@b27-mmr-17-02-3035]--[@b29-mmr-17-02-3035]) and a well-known mediator in numerous therapeutic and immuomodulatory functions, indicating a regulatory function of NO in primary and secondary immune organs. There are three isoforms of NO synthases (NOSs), which are neuronal (nNOS), inducible (iNOS) and endothelial (eNOS), and they are responsible for the synthesis of NO from the amino acid, l-arginine ([@b30-mmr-17-02-3035]). Previous studies have demonstrated that all three isoforms express enzymatic activity of NADPH-d ([@b31-mmr-17-02-3035],[@b32-mmr-17-02-3035]), and indicated the expression pattern of NADPH-d is an indirect indication of the presence of NOS and NO ([@b30-mmr-17-02-3035],[@b33-mmr-17-02-3035]). Therefore NADPH-d activity has been used as a marker for NOS.

Therefore, the current study was performed to determine whether 10 µM BetA modulates NO production or induces changes in healthy spleen and thymus cells in mice, and to investigate the possible functions of BetA in these organs. A histochemical analysis of NADPH-d, a marker for NOS, was also performed ([@b34-mmr-17-02-3035]).

Materials and methods
=====================

### Animals and reagents

Animal experiments were conducted in accordance with the National University of Malaysia (UKM; Kuala Lumpur, Malaysia) animal ethics guidelines and regulations laid out by the Institutional Animal Ethics Committee (UKMAEC; FF/2016/ALI/20-MAY/685-JUNE-2016). Six-week-old, female BALB/c mice procured from the institutional animal holding facility (n=196), were maintained (2--3 animals/cage) under pathogen-free conditions and a 12-h light/dark cycle, with access to commercial pellets and distilled water. BetA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) served as a test drug, goniothalamin (GTN; provided by Dr Ibrahim Jantan, Faculty of Pharmacy, UKM) served as a positive control drug, and dimethyl sulfoxide (DMSO; Merck KGaA) served as a vehicle.

### Animal treatment and sample collection

Animals were randomly divided into four main groups as follows: Experimental group (10 µM BetA; n=48), a positive control group (50 µM GTN; n=48), a negative control group (0.05% DMSO; n=48) and a normal standard control group (n=48). Each main group of animals was further divided into three equal subgroups (n=6 per group) corresponding to the treatment period (4, 8 and 12 days). Chloral hydrate (10%; i.p.) was administered to anesthetize the animals, subsequently animals were fixed using 4% paraformaldehyde and a transcardiac perfusion method described by Syed *et al* ([@b27-mmr-17-02-3035]). The fixed tissue blocks were maintained in the same fixative solution for a further 6 h as post fixation, followed by rinsing in 0.1 M phosphate buffer (PB) and cryoprotection in 30% sucrose. Finally, 10 µm frozen sections were sliced (Leica SM2010 Sliding microtome; Leica Microsystems GmbH, Wetzlar, Germany). Three series of sliced sections were collected on a glass slide and stained for NADPH-d.

### Histochemistry of NADPH-d and analysis of tissue morphology

Frozen tissue sections were maintained at room temperature for 30 min, washed twice in PB, followed by staining for NADPH-d with the addition of substrate β-NADPH \[Malaysia Sigma-Aldrich (M) Sdn. Bhd, Kuala Lumpur, Malaysia\] and nitroblue tetrazolium, a salt that yields an insoluble blue formazan precipitate visible under a light microscope ([@b27-mmr-17-02-3035]). In the case of NADPH-d histochemistry controls, sections were incubated at room temperature for 45 min in a β-NADPH-free medium. The intensity of the reaction in the thymus and spleen was determined by measurement of optical density (OD; 0--260 nm), using Olympus cellSens (Olympus Soft Imaging Solutions GmbH, Münster, Germany) software version 1.6, and was graphically represented. From each sample, three to four slides were subjected to the staining procedure and multiple areas were evaluated randomly using a light microscope. The cross-sectional morphology of the tissues was observed using an Olympus BX41TF microscope (Olympus Corp., Tokyo, Japan). Images of the sections were captured using an Olympus UC30, with Olympus cellSens software version 1.6. All measurements were performed in duplicate or triplicate and repeated at least three times.

### Statistical analysis

Statistical assessment of the intensity data was performed using one-way ANOVA followed by Bonferroni multiple comparison\'s tests (GraphPad Prism version 4.0; GraphPad Software, In., La Jolla, CA, USA). All numerical data are expressed as the mean ± standard error of the mean and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### NADPH-d expression in the thymus

Although the control group (DMSO-treated vehicle) received no drug treatment, weak or faint NADPH-d staining was observed in the cortex and medulla region of the thymus ([Fig. 2A-C](#f2-mmr-17-02-3035){ref-type="fig"}), whereas in the positive-control group (GTN), the capsule and cortex region demonstrated moderate NADPH-d expression 4 days after the GTN injection, which continuously increased at the eighth and twelfth day of treatment ([Fig. 2D-F](#f2-mmr-17-02-3035){ref-type="fig"}). This indicates that GTN induces time-dependent expression of NADPH-d in the thymus. However, the NADPH-d distribution was initially similar to that in the control group after day 4, and subsequently the distribution spread to the whole lobule on the eighth and twelfth day of treatment.

Similarly, a gradual increase of NADPH-d distribution (P\<0.001) was observed in the BetA treatment group and its activity increased along with longer BetA exposure ([Fig. 2G-I](#f2-mmr-17-02-3035){ref-type="fig"}). However, the thymus displayed only slight to moderate NADPH-d staining after 4 days ([Fig. 2G](#f2-mmr-17-02-3035){ref-type="fig"}), 8 days ([Fig. 2H](#f2-mmr-17-02-3035){ref-type="fig"}) and 12 days of BetA treatment ([Fig. 2I](#f2-mmr-17-02-3035){ref-type="fig"}), in the cortex and the medullary region. The interlobular septum extends from the capsule into the thymus, subdividing the thymus into interconnecting lobules, which are of varying size and orientation. The expression pattern of NADPH-d spread to a wider area at the medullary region across the septum 8 days after BetA treatment, demonstrating higher NADPH-d activity. As the septum is the site where blood vasculatures in the thymus are oriented, staining in this region ([Fig. 2C and G](#f2-mmr-17-02-3035){ref-type="fig"}) supports that NO has a role in vascular physiology. The graph ([Fig. 2J](#f2-mmr-17-02-3035){ref-type="fig"}) demonstrates the intensity (OD) per staining area (cm^2^) of the thymus tissue sections after 4, 8 and 12 days of treatment. Increased NADPH-d expression indicates that the effect of BetA on the thymus depends on exposure time.

### NADPH-d expression in the spleen

Compared with that in the control group ([Fig. 3A-C](#f3-mmr-17-02-3035){ref-type="fig"}), the spleen of the GTN ([Fig. 3D-F](#f3-mmr-17-02-3035){ref-type="fig"}) and BetA groups ([Fig. 3G-I](#f3-mmr-17-02-3035){ref-type="fig"}) demonstrated a particularly strong NADPH-d reaction, with increased expression levels in the cortex and medullary regions ([Fig. 3D-I](#f3-mmr-17-02-3035){ref-type="fig"}), as well as in the vasculature ([Fig. 3C, F and I](#f3-mmr-17-02-3035){ref-type="fig"}), which increased with longer exposure times. The spleen is enclosed by a fibro elastic outer connective tissue, the capsule, and composed of white and red pulp, forming two functionally and morphologically different units. The NADPH-d staining (brown precipitate) was more widely present in the red pulp than in the white pulp area. The red pulp region is comprised of various cells, including sinusoids ([@b35-mmr-17-02-3035]). The graph ([Fig. 3J](#f3-mmr-17-02-3035){ref-type="fig"}) demonstrates the intensity (OD) per staining area (cm^2^) of the spleen tissue sections after 4, 8 and 12 days of treatment

### Morphological changes

No phenotypical appearance or significant morphological changes were observed in either the GTN- or the BetA-treated thymus and spleen.

Discussion
==========

The present study demonstrated positive NADPH-d staining in the thymus and in the spleen of non-immunized GTN and BetA-treated mice. However, its expression and distribution pattern varied with these agents throughout the treatment period. Although no morphological or phenotypical changes were evident in these organs, the NADPH-d activity was more prominent in the spleen than in the thymus. The red pulp region of the spleen strongly expressed NADPH-d, whereas only a moderate reactivity was observed in the white pulp region. Although NADPH-d expression was detected after 4 days, a significant increase in expression was observed after 8 days of BetA treatment, indicating the contribution of NADPH-d in spleen NO generation during the entire treatment period. Similarly, a steady increase in NADPH-d activity in the thymus beginning from day 4 may specify an interactive outcome of NO on the thymus vascular and medulla regions, which may be involved in immune modulation ([@b33-mmr-17-02-3035],[@b36-mmr-17-02-3035]--[@b37-mmr-17-02-3035]). Although the function of NO in the thymus and spleen has not been demonstrated, the findings of the current study indicate that there is an association between the immunological effects induced by BetA. The major effect of BetA-induced NO appears to be involved in maintenance of the immune system ([@b38-mmr-17-02-3035]--[@b40-mmr-17-02-3035]) and the current results support other reports in which the presence of NO was demonstrated in the immune system ([@b33-mmr-17-02-3035],[@b41-mmr-17-02-3035]).

It has been demonstrated that the expression of NOS and production of NO are characteristic of cells involved in immune responses ([@b33-mmr-17-02-3035],[@b36-mmr-17-02-3035],[@b42-mmr-17-02-3035]). Although NO is less active in cells from normal mice ([@b43-mmr-17-02-3035]), a spleen cell subpopulation produces enough NO during an *in vitro* immune response to completely prevent multiplication of T cells ([@b44-mmr-17-02-3035],[@b45-mmr-17-02-3035]). Similarly, previous studies have demonstrated that a wide range of potential immunomodulatory functions may be expected for NO in the thymus, including the following: Induction of tolerance, restriction of major histocompatibility complex, lymphocyte trafficking and regulation of thymic endocrine output ([@b33-mmr-17-02-3035],[@b36-mmr-17-02-3035],[@b37-mmr-17-02-3035],[@b42-mmr-17-02-3035]). Furthermore, if there are effects or changes in the cells due to BetA treatment, it is assumed that NO may be produced to perform its regulatory roles in the cells of these immune organs.

Betulin and BetA trigger and modify cytokine production in human whole blood cell cultures ([@b46-mmr-17-02-3035]). To support this hypothesis, previous studies have reported that BetA augments mouse immune function, including cellular and humoral immunity, and activity of phagocytic macrophages ([@b39-mmr-17-02-3035],[@b47-mmr-17-02-3035]). BetA was identified as a modulatory agent of cytokine production by T helper cells (Th1/Th2) and other immune cells in animals. Consistently, the results of numerous studies indicated that BetA may be useful for modulation of the immune system ([@b40-mmr-17-02-3035],[@b48-mmr-17-02-3035]--[@b51-mmr-17-02-3035]). Furthermore, various bioactive materials derived from other plants exhibit immunomodulatory abilities ([@b52-mmr-17-02-3035]--[@b55-mmr-17-02-3035]).

In addition, NO is recognized to act as a vasodilator following its release from endothelial cells ([@b56-mmr-17-02-3035]--[@b58-mmr-17-02-3035]), including BetA-treated endothelial cells ([@b59-mmr-17-02-3035]--[@b62-mmr-17-02-3035]). This function is mediated by NO inhibitory action on vascular smooth muscles. However, Moncada *et al* ([@b25-mmr-17-02-3035]) and other studies ([@b63-mmr-17-02-3035],[@b64-mmr-17-02-3035]) have demonstrated that NO-mediated vasodilation occurs without endothelial cells present, where the NO-positive nitrergic nerves may act directly on smooth muscle cells, leading to vasodilation. Such control by neuronal NO has also been demonstrated in the peripheral nervous system ([@b65-mmr-17-02-3035],[@b66-mmr-17-02-3035]).

The innervation of NO-positive perivascular nerves has also been demonstrated in many types of vascular tissue ([@b67-mmr-17-02-3035]--[@b69-mmr-17-02-3035]). The distribution of supply of nerves in the thymus are not entirely known; however, previous studies focused on the neural structures contained within the thymus ([@b70-mmr-17-02-3035],[@b71-mmr-17-02-3035]). The activity of NADPH-d was demonstrated in many parts of the nervous system in mammals ([@b72-mmr-17-02-3035]--[@b74-mmr-17-02-3035]). The present results are consistent with previous findings that NADPH-d-labelled cells are present in the rat thymus ([@b28-mmr-17-02-3035],[@b30-mmr-17-02-3035],[@b75-mmr-17-02-3035]). Although the current study observed NADPH-d-stained nerve fibers in the perivascular area, no NADPH-d neuronal cell body-like structures were observed in either the thymus or the spleen. The moderate distribution of NO-containing nerves travelling along blood vessels may reflect a particularly significant role that neuronal NO may perform in controlling blood flow through the thymus and spleen. The fact that NO-positive nerves and the vascular endothelium may produce NO to influence blood flow has been described in the nervous system ([@b74-mmr-17-02-3035]), pancreas ([@b76-mmr-17-02-3035]), thyroid ([@b27-mmr-17-02-3035],[@b29-mmr-17-02-3035]) and various other tissues. This observation indicates that NO participates in neurotransmission in the thymus and spleen. It is important to note that in addition to blood vessels, NO may regulate the secretory activity of immune cells by its generation in these cells ([@b77-mmr-17-02-3035]). Thus, BetA may present a promising biological response modifier and may reinforce the immune response of a host.

In conclusion, the current study demonstrates that BetA treatment induces the expression of NADPH-d activity in the thymus and spleen without causing any significant changes to the morphology of the organs. These findings are of direct clinical relevance and may contribute to the progression of drug discovery. To the best of our knowledge, this is the most significant study describing BetA-induced, NADPH-d-mediated NO signaling, which may be the mechanism underlying BetA-elicited immunomodulation in these organs.
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![Structure of triterpenoid alcohol betulin and the corresponding carboxylic acid betulinic acid.](MMR-17-02-3035-g00){#f1-mmr-17-02-3035}

![Representative photomicrographs demonstrating thymus sections of the (A-C) VC (dimethyl sulfoxide), (D-F) positive (GTN) and (G-I) BetA-treated groups on days 4, 8 and 12 after treatment. Inset (IS) is representative of the area in the figure outlined in black. Black arrows identify the NADPH-d-stained blood vessels (BV), the red arrow points the perivascular nerve fibres and blue arrow demonstrates the NADPH-d positive cells in the cortex (denoted by the letter C) and medulla (denoted by the letter M). The letter 'S' indicates the interlobular septum. Scale bar, 100 µm. (J) The intensity (OD) of the NADPH-d staining was quantified using Olympus Soft Imaging cellSens software version 1.6. Data are expressed as means ± standard deviation of mice (n=6 per group) \*\*P\<0.001 vs. the VC group, ^\#^P\<0.001 vs. the GTN group. †P\<0.01 vs. the VC group. GTN, goniothalamin; BetA, betulinic acid; NADPH-d, nicotinamide adenine dinucleotide phosphate diaphorase; VC, vehicle control; OD, optical density.](MMR-17-02-3035-g01){#f2-mmr-17-02-3035}

![Representative photomicrographs demonstrating spleen sections the (A-C) VC (dimethyl sulfoxide), (D-F) positive (GTN) and (G-I) BetA-treated groups on days 4, 8 and 12 after treatment. Inset (IS) is representative of the area in the figure outlined in black. Black arrows identify the NADPH-d-stained blood vessels (BV), the red arrow points the perivascular nerve fibres and blue arrow demonstrates the NADPH-d positive cells in the red pulp (RP) region. 'WP' indicates the white pulp region. Scale bar, 100 µm. (J) The intensity (OD) of the NADPH-d staining was quantified using Olympus Soft Imaging cellSens software version 1.6. Data are expressed as means ± standard deviation of mice (n=6 per group) \*\*P\<0.001 vs. the VC group, ^\#^P\<0.001 vs. the GTN group, ^†^P\<0.01 vs. the VC group. GTN, goniothalamin; BetA, betulinic acid; NADPH-d, nicotinamide adenine dinucleotide phosphate diaphorase; VC, vehicle control; OD, optical density.](MMR-17-02-3035-g02){#f3-mmr-17-02-3035}
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